CD274 and neoplasm: Nevertheless, by combining MYC inactivation with anti-PD-L1 therapy, we significantly delayed tumor recurrence, extending median survival by ~25% compared to the isotype treated group (69 days in MYC-OFF + isotype antibody vs. 88 days in MYC-OFF + anti-PDL1) (Fig. 1f).